Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Equity Average (2016 - 2025)

Iradimed (IRMD) has disclosed Equity Average for 12 consecutive years, with $96.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average rose 18.12% to $96.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $96.3 million, a 18.12% increase, with the full-year FY2024 number at $79.1 million, up 9.06% from a year prior.
  • Equity Average was $96.3 million for Q3 2025 at Iradimed, up from $92.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $96.3 million in Q3 2025 to a low of $62.2 million in Q1 2021.
  • A 5-year average of $74.2 million and a median of $71.7 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: increased 0.36% in 2022, then grew 19.88% in 2025.
  • Iradimed's Equity Average stood at $70.0 million in 2021, then rose by 2.41% to $71.7 million in 2022, then grew by 1.77% to $73.0 million in 2023, then grew by 16.62% to $85.1 million in 2024, then rose by 13.16% to $96.3 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Equity Average are $96.3 million (Q3 2025), $92.2 million (Q2 2025), and $88.4 million (Q1 2025).